[Dyslipidemias: new therapeutic targets and relevance of combination therapies]
Related Experiment Video
Updated: Nov 9, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Marcello Arca1, Stefania Angela Di Fusco2
1Dipartimento di Medicina Traslazionale e di Precisione, Sapienza Università di Roma, Roma.
Insights
New guidelines lower low-density lipoprotein cholesterol (LDL-C) targets for high-risk patients. Real-world data show a gap in achieving these LDL-C goals, highlighting the need for combination therapies and new drugs like bempedoic acid.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Growing evidence links lower low-density lipoprotein cholesterol (LDL-C) levels to improved patient prognosis.
- Updated 2019 European Society of Cardiology guidelines have intensified LDL-C targets for individuals at higher cardiovascular risk.
Purpose of the Study:
- To address the discrepancy between guideline-recommended LDL-C targets and real-world achievement.
- To explore effective therapeutic strategies for managing hypercholesterolemia in high-risk populations.
Main Methods:
- Analysis of national and international observational clinical studies.
- Review of current treatment strategies and emerging pharmacological options for lipid management.
Main Results:
- Significant gap identified between recommended and achieved LDL-C levels in real-world settings, particularly for high-risk patients.
- Combination treatment strategies are effective and safe for reaching target LDL-C levels.
Conclusions:
- Combination therapy with multiple lipid-lowering drugs is crucial for achieving guideline-recommended LDL-C targets.
- New agents, including bempedoic acid, expand therapeutic options for hypercholesterolemia management.
Abstract:
Based on growing evidence showing a better prognosis in individuals with lower levels of low-density lipoprotein cholesterol (LDL-C), updated 2019 European Society of Cardiology guidelines have further reduced LDL-C targets in patients with higher cardiovascular risk. National and international observational clinical studies demonstrated a significant gap between goals recommended by international guidelines and LDL-C levels achieved in the real world, especially in patient populations at higher risk. Combination treatment strategies with more lipid-lowering drugs represent effective and safe options for the achievement of recommended targets. The introduction of new drugs, such as bempedoic acid, further expands the available therapeutic armamentarium for hypercholesterolemia management.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipids: Dietary Sources and Requirements
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

